Figure S2 from Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
Year: 2023
Type: other
Abstract: Tumor infiltrating lymphocytes (TIL) were isolated 5 days post adoptive transfer according to the materials and methods section. Cells were gated for Thy1.2 expression. A) Galectin-3 wildtype (WT) high avidity CD8+ T cells were adoptively transferred into either galectin-3 WT (red) or galectin-3 KO neu-N (blue) recipient mice. Histogram overlays show differences in galectin-3 MFI between the two groups with respect to isotype control staining (orange). B) Galectin-3 staining is now shown on galectin-3 KO high avidity CD8+ T cells adoptively transferred into a galectin-3 KO neu-N recipient (blue) with respect to an isotype control (red). C) TCR avidity is compared between galectin-3 WT high avidity CD8+ T cells from a galectin-3 WT neu-N recipient and galectin-3 KO high avidity CD8+ T cells from a galectin-3 KO neu-N recipient. TCR avidity was assessed by staining with a 1:100 dilution of MHC I Dq tetramer loaded with the RNEU420-429 (P50) peptide. This experiment was repeated twice with similar results. D) Histogram overlays demonstrating differences in surface galectin-3 MFI on adoptively transferred high avidity tumor specific CD8+ T cells (Thy1.2+) vs. endogenous CD8+ T cells in the tumor microenvironment (Thy1.2-)
Authors: Theodore Kouo, Lanqing Huang, Alexandra B. Pucsek, Minwei Cao, Sara Solt, Todd Armstrong, Elizabeth Jaffee
Language: English
Topic: Galectins and Cancer Biology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362567239